ACHONDROPLASIA
Clinical trials for ACHONDROPLASIA explained in plain language.
Never miss a new study
Get alerted when new ACHONDROPLASIA trials appear
Sign up with your email to follow new studies for ACHONDROPLASIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for boosting growth in kids with dwarfism
Disease control CompletedThis study tested a daily oral drug called infigratinib in 114 children aged 3 to 18 with achondroplasia, the most common form of dwarfism. The goal was to see if it could safely increase their growth rate compared to a placebo. The trial is now complete, and results will show wh…
Matched conditions: ACHONDROPLASIA
Phase: PHASE3 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New weekly injection shows promise for boosting growth in kids with dwarfism
Disease control CompletedThis study tested a once-weekly injection called TransCon CNP in 84 children aged 2 to 11 with achondroplasia, the most common form of dwarfism. The goal was to see if it safely increases growth rate over a year compared to a placebo. After the first year, all children could rece…
Matched conditions: ACHONDROPLASIA
Phase: PHASE2, PHASE3 • Sponsor: Ascendis Pharma Growth Disorders A/S • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug shows promise for boosting growth in kids with dwarfism
Disease control CompletedThis study tested an oral drug called infigratinib in 84 children aged 3 to 11 with achondroplasia, the most common form of dwarfism. The goal was to see if it could safely increase their growth rate. Children took the drug daily, and researchers measured height changes and side …
Matched conditions: ACHONDROPLASIA
Phase: PHASE2 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
No treatment, just tracking: PROPEL study watches how kids with achondroplasia grow
Knowledge-focused CompletedThis study followed 271 children with achondroplasia, ages 2.5 to 17, to understand their growth, medical issues, and quality of life over time. No medication or treatment was given. The goal was to gather natural history data to help design future clinical trials.
Matched conditions: ACHONDROPLASIA
Sponsor: QED Therapeutics, a BridgeBio company • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC